AKT1 and breast cancer: Since the ERα/Src/PI3K complex is highly expressed in aggressive ERα-positive breast cancers [20] and activation of the PI3K/Akt pathway is involved in resistance to endocrine therapies [26,27], we speculated that the activation of oestrogen non-genomic signalling was implicated in such resistance.